In this video, IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope Cancer Center – Scottsdale, AZ, USA) provides an overview of the top myeloma-related abstracts from the 2021 American Clinical Society of Oncology (ASCO) and 2021 European Hematology Association (EHA) annual meetings.
He discusses optimal induction therapies for myeloma, the continuous use of autologous stem cell transplant as a standard of care in myeloma, the role of maintenance therapy, and best options for high-risk multiple myeloma. Dr. Mikhael also covers CAR T-cell therapy and bispecific therapies.
He points to the results of MAIA study, a late-breaking abstract from the EHA meeting, to shed light on long-term management of the disease.
Improving Lives Through Research and Patient Care
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma
Visit our website at: https://www.myeloma.org
Find us online:
Facebook: @myeloma | https://facebook.com/myeloma
Twitter: @IMFMyeloma | https://twitter.com/IMFmyeloma
Instagram: @imfmyeloma | https://www.instagram.com/imfmyeloma
Support the IMF! http://bit.ly/WskQHC
Nonprofits & Activism
Standard YouTube License